DNA methyltransferase inhibitor exposure–response: Challenges and opportunities
Clinical and Translational Science · 2023-08 · 16 (8) · 1309-1322
DOI: 10.1111/cts.13548 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical and Translational Science, online erschienen am 21.06.2023. Verfasst von Amanda B Kagan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Azacitidine, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, NCATS NIH HHS, NIGMS NIH HHS.
Abstract (Originalsprache)
Although DNA methyltransferase inhibitors (DNMTis), such as azacitidine and decitabine, are used extensively in the treatment of myelodysplastic syndromes and acute myeloid leukemia, there remain unanswered questions about DNMTi's mechanism of action and predictors of clinical response. Because patients often remain on single‐agent DNMTis or DNMTi‐containing regimens for several months before knowing whether clinical benefit can be achieved, the development and clinical validation of response‐predictive biomarkers represents an important unmet need in oncology. In this review, we will summarize the clinical studies that led to the approval of azacitidine and decitabine, as well as the real‐world experience with these drugs. We will then focus on biomarker development for DNMTis—specifically, efforts at determining exposure–response relationships and challenges that remain impacting the broader clinical translation of these methods. We will highlight recent progress in liquid‐chromatography tandem mass spectrometry technology that has allowed for the simultaneous measurement of decitabine genomic incorporation and global DNA methylation, which has significant potential as a mechanism‐of‐action based biomarker in patients on DNMTis. Last, we will cover important research questions that need to be addressed in order to optimize this potential biomarker for clinical use.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Oncology, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
- Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
- The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland, USA.
- Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, Ohio, USA.
ORCID-Profile: Amanda B Kagan, Dominique A Garrison, Michelle A Rudek
Förderung
- NCI NIH HHS
- NCATS NIH HHS
- NIGMS NIH HHS
Zitieren
APA
Kagan, A. B., Garrison, D. A., Anders, N. M., Webster, J. A., Baker, S. D., Yegnasubramanian, S., & Rudek, M. A. (2023). DNA methyltransferase inhibitor exposure–response: Challenges and opportunities. Clinical and Translational Science, 16(8), 1309-1322. https://doi.org/10.1111/cts.13548
Vancouver
Kagan AB, Garrison DA, Anders NM, Webster JA, Baker SD, Yegnasubramanian S, et al. DNA methyltransferase inhibitor exposure–response: Challenges and opportunities. Clinical and Translational Science. 2023;16(8):1309-1322. doi:10.1111/cts.13548
BibTeX
@article{Kagan2023,
author = {Kagan, Amanda B and Garrison, Dominique A and Anders, Nicole M and Webster, Jonathan A and Baker, Sharyn D and Yegnasubramanian, Srinivasan and Rudek, Michelle A},
title = {DNA methyltransferase inhibitor exposure–response: Challenges and opportunities},
journal = {Clinical and Translational Science},
year = {2023},
volume = {16},
number = {8},
pages = {1309--1322},
doi = {10.1111/cts.13548}
}
EUVIMED